A vanishing act: the incredible erlotinib.

doi:10.4103/0973-1482.103539

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A vanishing act: the incredible erlotinib.

Journal of cancer research and therapeutics - 1 Jan 2000

Arora Shitij, Sawhney Harinder

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Deoxycytidine
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gemcitabine

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Share to Smoking

Source

Open in PubMed

Identifiers

PMID: 23174741
DOI: 10.4103/0973-1482.103539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A vanishing act: the incredible erlotinib.PMID 23174741Read ↗

Erlotinib.Semantic proximity Read ↗

Therapeutics: a glimpse of the future.Semantic proximity Read ↗

The case for eteplirsen: Paving the way for precision medicine.Semantic proximity Read ↗

[Individualized drug therapy].Semantic proximity Read ↗

Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?Semantic proximity Read ↗

KRAS: Druggable at Last.Semantic proximity Read ↗

DRUG REPURPOSING-Overcoming the translational hurdles to clinical use.Semantic proximity Read ↗

When good drugs go bad.Semantic proximity Read ↗

Resistance: Crizotinib makes a comeback.Semantic proximity Read ↗

Selpercatinib.Semantic proximity Read ↗

PARP inhibitors: the story is still unfolding.Semantic proximity Read ↗

Drug-induced effects on erlotinib metabolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.